Literature DB >> 31748420

The biology of pulmonary exacerbations in bronchiectasis.

Francesco Amati1,2, Edoardo Simonetta1,2, Andrea Gramegna1,2, Paolo Tarsia1,2, Martina Contarini1,2, Francesco Blasi1,2, Stefano Aliberti3,2.   

Abstract

Bronchiectasis is a heterogeneous chronic disease. Heterogeneity characterises bronchiectasis not only in the stable state but also during exacerbations, despite evidence on clinical and biological aspects of bronchiectasis, exacerbations still remain poorly understood.Although the scientific community recognises that bacterial infection is a cornerstone in the development of bronchiectasis, there is a lack of data regarding other trigger factors for exacerbations. In addition, a huge amount of data suggest a primary role of neutrophils in the stable state and exacerbation of bronchiectasis, but the inflammatory reaction involves many other additional pathways. Cole's vicious cycle hypothesis illustrates how airway dysfunction, airway inflammation, infection and structural damage are linked. The introduction of the concept of a "vicious vortex" stresses the complexity of the relationships between the components of the cycle. In this model of disease, exacerbations work as a catalyst, accelerating the progression of disease. The roles of microbiology and inflammation need to be considered as closely linked and will need to be investigated in different ways to collect samples. Clinical and translational research is of paramount importance to achieve a better comprehension of the pathophysiology of bronchiectasis, microbiology and inflammation both in the stable state and during exacerbations.
Copyright ©ERS 2019.

Entities:  

Mesh:

Year:  2019        PMID: 31748420     DOI: 10.1183/16000617.0055-2019

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  10 in total

1.  Traction bronchiectasis: is it as benign as we think?

Authors:  Amina Bekki; Thais Beauperthuy; Miguel Ángel Martínez-García
Journal:  J Bras Pneumol       Date:  2022-07-25       Impact factor: 2.800

2.  Mutagenic damage among bronchiectasis patients attending in the pulmonology sector of a hospital in southern Brazil.

Authors:  Daniel Wenceslau Votto Olmedo; Katheryne Benini Martins; Milene Machado Paz; Caroline Lopes Feijo Fernandes; Flavio Manoel Rodrigues da Silva Júnior; Daniela Fernandes Ramos
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-09       Impact factor: 1.712

3.  Daily versus three-times-weekly azithromycin in Chinese patients with non-cystic fibrosis bronchiectasis: protocol for a prospective, open-label and randomised controlled trial.

Authors:  Yanxiong Mao; Lan Chen; Ting He; Jing Li; Aiping Zou; Feng Li; Fei Chen; Bo Fan; Weihao Ni; Wei Xiao; Huimin You; Wenjiang Fu
Journal:  BMJ Open       Date:  2022-07-08       Impact factor: 3.006

Review 4.  Intermittent prophylactic antibiotics for bronchiectasis.

Authors:  Sally Spencer; Tim Donovan; James D Chalmers; Alexander G Mathioudakis; Melissa J McDonnell; Anthony Tsang; Peter Leadbetter
Journal:  Cochrane Database Syst Rev       Date:  2022-01-05

5.  Neutrophils to Lymphocyte Ratio as a Biomarker in Bronchiectasis Exacerbation: A Retrospective Study.

Authors:  Vasiliki E Georgakopoulou; Nikolaos Trakas; Christos Damaskos; Nikolaos Garmpis; Evgenia Karakou; Rea Chatzikyriakou; Panagiota Lambrou; Xanthi Tsiafaki
Journal:  Cureus       Date:  2020-08-13

6.  Dynamic Upper and Lower Airway Microbiotas in Paediatric Bronchiectasis Exacerbations: A Pilot Study.

Authors:  David T J Broderick; Tyler Regtien; Alana Ainsworth; Michael W Taylor; Naveen Pillarisetti
Journal:  Front Cell Infect Microbiol       Date:  2022-01-24       Impact factor: 5.293

Review 7.  Protease-Antiprotease Imbalance in Bronchiectasis.

Authors:  Martina Oriano; Francesco Amati; Andrea Gramegna; Anthony De Soyza; Marco Mantero; Oriol Sibila; Sanjay H Chotirmall; Antonio Voza; Paola Marchisio; Francesco Blasi; Stefano Aliberti
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

8.  Clinical and research priorities for children and young people with bronchiectasis: an international roadmap.

Authors:  Anne B Chang; Jeanette Boyd; Leanne Bell; Vikas Goyal; I Brent Masters; Zena Powell; Christine Wilson; Angela Zacharasiewicz; Efthymia Alexopoulou; Andrew Bush; James D Chalmers; Rebecca Fortescue; Adam T Hill; Bulent Karadag; Fabio Midulla; Gabrielle B McCallum; Deborah Snijders; Woo-Jung Song; Thomy Tonia; Keith Grimwood; Ahmad Kantar
Journal:  ERJ Open Res       Date:  2021-07-19

Review 9.  Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases.

Authors:  Francesco Amati; Anna Stainer; Marco Mantero; Andrea Gramegna; Edoardo Simonetta; Giulia Suigo; Antonio Voza; Anoop M Nambiar; Umberto Cariboni; Justin Oldham; Philip L Molyneaux; Paolo Spagnolo; Francesco Blasi; Stefano Aliberti
Journal:  Int J Mol Sci       Date:  2022-01-17       Impact factor: 5.923

10.  Profile of Clinical and Analytical Parameters in Bronchiectasis Patients during the COVID-19 Pandemic: A One-Year Follow-Up Pilot Study.

Authors:  Liyun Qin; Filipe Gonçalves-Carvalho; Yingchen Xia; Jianhua Zha; Mireia Admetlló; José María Maiques; Sandra Esteban-Cucó; Xavier Duran; Alicia Marín; Esther Barreiro
Journal:  J Clin Med       Date:  2022-03-21       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.